Nuzyra (omadacycline) / ZAI Lab, Paratek Pharmaceuticals - LARVOL DELTA

Clinical Features and Treatment Differences Among Tuberculous, Brucellosis, and Pyogenic Spondylitis: A Cohort Study. (PubMed, Infect Drug Resist) - "Patients of spinal infections with diverse etiologies presented varied clinical features and risk factors, the treatment should be individualized. Due to the long course of treatment, ADRs need to be monitored during treatment, and newer drugs such as omadacycline and contezolid are efficacious and have favorable safety profiles."

Journal • Infectious Disease • Inflammatory Arthritis • Pain • Septic Shock • Seronegative Spondyloarthropathies

Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance. (PubMed, Drugs R D) - "Omadacycline is a novel tetracycline with a wide range of antibacterial activity. The review offers a thorough analysis of the many elements influencing the pharmacokinetics of omadacycline, including its intrinsic properties, individual differences, dietary influences, and possible drug interactions. To achieve maximum efficacy and safety in clinical practice, a thorough understanding of the pharmacokinetic properties of omadacycline is essential, which helps to better customize dosing regimens and maximize therapeutic outcomes."

Journal • PK/PD data • Review

Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease. (PubMed, Microbiol Spectr) - "The treatment guidelines include tetracyclines as part of the combination. While eravacycline MICs and static concentrations suggest great potential and even activity better than omadacycline and tigecycline, the drug only killed 0.56 log10 CFU/mL below stasis in the HFS-MAB. Monte Carlo simulation experiments suggested that optimal doses for MAB pulmonary disease are likely in the range that would not be tolerated by patients."

Journal • PK/PD data • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Case Report: Omadacycline in the Treatment of Community-Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies. (PubMed, Clin Case Rep) - "This case report presents a 4-year-old girl with a mixed infection of CAP who exhibited hypersensitivity to multiple antimicrobial agents (piperacillin-tazobactam, ceftazidime, fosfomycin, meropenem, and levofloxacin), was treated with omadacycline followed by doxycycline, and underwent bronchoscopy with bronchoalveolar lavage. Potential adverse effects of omadacycline were evaluated, along with its utilization and dosage in children. Omadacycline has the potential to be a viable alternative anti-infective agent for the treatment of pediatric CAP in the absence of other drug options and with adequate safety evaluation and monitoring."

Journal • Allergy • Immunology • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases

A Persistent Problem: Mycobacterium abscessus Infection of an Orthopedic Device after Trauma. (PubMed, Mil Med) - "After a multitude of surgeries, including orthopedic hardware removal from the forearm, and concurrent antibiotic therapy of amikacin, imipenem, tedizolid, and omadacycline, the patient was deemed medically cleared of her infection. This has implications for both civilian and military battlefield-related trauma infections. This case serves as an example of successful multi-disciplinary management through appropriately aggressive surgery and tailored antibiotic therapy."

Journal • Infectious Disease • Musculoskeletal Diseases • Nontuberculous Mycobacterial Disease • Orthopedics

Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients. (PubMed, Front Pharmacol) - "Omadacycline possesses favorable efficacy and safety for the treatment of infectious diseases. Baseline age, malignancy history, renal function, mechanical ventilation, ICU, LOS, and omadacycline use duration are strong predictors of clinical success."

Journal • Real-world evidence • Retrospective data • Acute Kidney Injury • Critical care • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Nephrology • Oncology • Renal Disease

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. (PubMed, EClinicalMedicine) - P3 | "75A50120C00001. The contract and federal funding are not an endorsement of the study results, products, or company."

Head-to-Head • Journal • P3 data • CNS Disorders • Infectious Disease • Insomnia • Pain • Pneumonia • Respiratory Diseases • Sleep Disorder

Non-genitourinary Ureaplasma urealyticum infections in solid organ transplant recipients: a case report and literature review. (PubMed, BMC Infect Dis) - "There is a possibility of severe U. urealyticum infection in patients with immunodeficiency after organ transplantation. Monitoring ammonia levels, utilizing rapid diagnostics, and initiating prompt treatment are all crucial to improving prognosis and reducing severe nerve damage, organ dysfunction, and mortality."

Journal • Infectious Disease • Solid Organ Transplantation • Transplantation

Eravacycline and omadacycline Rescue multidrug-resistant Elizabethkingia anophelis: Triple-Model evaluation across in Vitro, Galleria mellonella, and murine bacteremia systems. (PubMed, J Adv Res) - "These findings substantiate the robust antimicrobial efficacy of eravacycline and omadacycline against E. anophelis, offering valuable insights for optimizing clinical management. They provide compelling proof-of-concept that fluorocyclines eradicate multidrug-resistant E. anophelis in vitro and in vivo, strongly supporting clinical trial investigation."

Journal • Preclinical • Infectious Disease

Comparison of Efficacy and Safety Profiles Between Omadacycline and Moxifloxacin in Elderly Patients with Community-Acquired Pneumonia: A Randomized, Controlled Trial. (PubMed, Clin Pharmacol Drug Dev) - "No difference was observed in liver, kidney, and coagulation function parameters between the two groups (all P >  .05). Omadacycline indicates greater treatment efficacy and comparable safety profiles versus moxifloxacin in elderly patients with CAP."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases • CRP • IL6

Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease. (PubMed, Am J Health Syst Pharm) - "At clinical concentrations of agents used in the treatment of pulmonary M. abscessus disease, omadacycline appears to be physically compatible in dual-agent combinations in Y-site infusion with amikacin, azithromycin, cefoxitin, imipenem/cilastatin, and linezolid, as well as in triple combinations of omadacycline plus imipenem/cilastatin and amikacin and omadacycline plus linezolid and amikacin."

Journal • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

A Rare Case of Mycobacterium abscessus Peritoneal Dialysis-Associated Peritonitis (KIDNEY WEEK 2025) - "The patient was initially treated with oral antibiotics, and shortly after, with vancomycin through her PD catheter and Keflex...The patient began hemodialysis (HD) thrice weekly and was initiated on an antibiotic regimen of 500 mg azithromycin daily, 300 mg omadacycline daily, 500 mg IV imipenem every 12 hours, and amikacin...The described treatment plan for M. abscessus PD-associated peritonitis highlights the importance of culture-directed antibiotic therapy, particularly that of an amikacin-led regimen. This case additionally emphasizes the need for multiple modalities of dialysis, as removal of the contaminated catheter and proper recovery of the wound site prompted a switch to HD."

Clinical • Asthma • Chronic Kidney Disease • Constipation • Diabetic Nephropathy • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases

Cost-effectiveness of omadacycline versus moxifloxacin as the initial treatment for community-acquired bacterial pneumonia in China. (PubMed, Int J Clin Pharm) - "Omadacycline is not cost-effective compared to moxifloxacin as the initial treatment for CABP in China, unless significant price reductions are achieved."

HEOR • Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies. (PubMed, J Antimicrob Chemother) - "Omadacycline demonstrated in vitro activity against M. avium, particularly in combination with amikacin. Emergence of clarithromycin and amikacin resistance seemed to be prevented by co-exposure to omadacycline. Further research is warranted to assess omadacycline's role in treating M. avium disease."

Journal • Preclinical • Infectious Disease

Anti-IFN-gamma Autoantibodies In An Adult Patient With Disseminated Mycobacterium Abscessus Infection (ACAAI 2025) - "Supraclavicular lymph node biopsy showed inflammation with sclerosis, and cultures grew M. abscessus , prompting initiation of amikacin, meropenem, and omadacycline. Seven months later, patient had radiographic and clinical improvement and was transitioned to oral omadacycline and tedizolid for minimum twelve-month course...Identification of anti-IFN-γ autoantibodies is critical given the role of immunomodulatory therapies including rituximab and IFN-γ in patients with antimicrobial-refractory infections. Most recently, CAAR T cell therapy has shown promise in averting anti-IFN-γ autoantibody-related infections by targeting self-reactive B cells."

Clinical • Asthma • Cough • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Tetanus • Tuberculosis • CD4 • CSF2 • IFNG

A Case: Hepatic Abscesses and Cholecystitis Secondary to Hereditary Angioedema (ACAAI 2025) - "Case Description A 75-year-old male with HAE type I presented with throat swelling after missing two doses of lanadelumab...Treatment consisted of icatibant, cefepime, metronidazole and bowel decompression...He improved and was discharged on omadacycline with outpatient follow-up...Upon continued symptoms, repeat imaging showed hepatic abscess development likely from bacterial translocation from gut edema and resulting cholecystitis complications 2 . This case showcases the multitude of complications that may arise in HAE patients."

Clinical • Cardiovascular • Complement-mediated Rare Disorders • Gastroenterology • Gastrointestinal Disorder • Hepatology • Hereditary Angioedema • Infectious Disease

A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria. (PubMed, Eur Respir Rev) - "There remains a significant unmet need for effective, well-tolerated therapies for the treatment of NTM, especially those that improve quality of life. Although tetracyclines have not been evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease and further RCTs are warranted."

Journal • Review • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease. (PubMed, J Antimicrob Chemother) - "Epetraborole microbial kill is the best, thus far, achieved in the HFS-MAB, more than two times omadacycline's 123 cfu/mL below B0. We propose to test a novel combination regimen of epetraborole plus omadacycline plus a β-lactam versus GBT first in the HFS-MAB, followed by clinical trials."

Journal • Preclinical • Pulmonary Disease • Respiratory Diseases

Omadacycline treatment of severe Chlamydia psittaci pneumonia with septic shock diagnosed via metagenomic next-generation sequencing. (PubMed, J Infect Dev Ctries) - "Our findings highlight the potential of mNGS for rapid diagnosis of Chlamydia psittaci pneumonia and suggest omadacycline as a potential therapeutic option for severe cases that do not respond to conventional treatment."

Biomarker • Journal • Next-generation sequencing • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock

A multicenter, prospective, randomized controlled trial evaluating β-lactam combined with omadacycline for the treatment of severe community-acquired pneumonia. (ChiCTR) - P=N/A | N=248 | Recruiting | Sponsor: The Fifth Medical Center of the PLA General Hospital; The Fifth Medical Center of the PLA General Hospital

New trial • Infectious Disease • Pneumonia • Respiratory Diseases

A COMPLEX ONGOING CASE OF MEDICAL MANAGEMENT OF EXTENSIVE, RECALCITRANT CAVITARY MYCOBACTERIUM ABSCESSUS LUNG DISEASE (CHEST 2025) - "This isolate was sensitive to amikacin, clofazimine, imipenem, and tigecycline and resistant to cephalosporins...He was started on intensive therapy with IV tigecycline/imipenem and clofazimine in 2020 for four months with clinical and radiologic improvement, then switched to oral continuation therapy with clofazimine and omadacycline to allow him to travel for performances... M. abscessus requires years long intensive, parenteral multidrug regimens, but in some cases, continuous treatment with alternating intensive and continuation phases may be used to accomplish clinical and radiologic improvement for years while allowing for improved quality of life and functionality and limiting drug toxicity. Further research is needed validate new drug combinations for the management of M. abscessus related lung disease."

Clinical • CNS Disorders • Cough • Nontuberculous Mycobacterial Disease • Psychiatry • Pulmonary Disease • Respiratory Diseases • Schizophrenia

LETTING NTM PULL ON YOUR QTC STRINGS (CHEST 2025) - "She was ultimately transitioned to oral consolidation therapy via PO Clofazimine and Bedaquiline due to intolerability of Omadacycline (nausea/vomiting), Amikacin (epistaxis), and Linezolid (neuropathy)...Subsequently, she was again trialed on Azithromycin, Ethambutol, and Rifampin, with her QTc remaining acceptable... From this case, we can conclude that, in appropriate patient populations, it is reasonable to utilize Mexiletine (or other late sodium current blockers) to shorten the QT interval in patients who require MAC pharmacotherapy with QTc-prolonging agents."

Cardiovascular • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. (PubMed, BMC Infect Dis) - "Our findings indicate that omadacycline is a promising treatment option for ABSSSI, demonstrating efficacy that is comparable to or potentially superior to many other anti-MRSA agents, along with a favorable safety profile. However, these results should be interpreted with caution due to the study's inherent limitations."

Clinical • Journal • Retrospective data • Review • Infectious Disease

HYDROPNEUMOTHORAX CAUSED BY A RUPTURED MYCOBACTERIUM ABSCESSUS EMPYEMA, REQUIRING ROBOTIC VATS DECORTICATION, IN A PATIENT WITH CYSTIC FIBROSIS ON TRIKAFTA (CHEST 2025) - "Initial treatment included linezolid and piperacillin-tazobactam, later escalated to meropenem...A pigtail drain was placed and his regimen escalated to meropenem, azithromycin, amikacin, and eravacycline...Newer agents, like eravacycline and omadacycline, offer promise for treatment of multidrug-resistant infections [19]... This case underscores the complexities of M. abscessus infection in CF, requiring aggressive antimicrobial therapy and surgical intervention. Close monitoring is essential for early diagnosis. Genomic sequencing and new emerging antibiotics hold promise for future improved outcomes."

Clinical • Cystic Fibrosis • Febrile Neutropenia • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii. (PubMed, Antimicrob Agents Chemother) - "We evaluated the in vitro activity of omadacycline against A. baumannii clinical isolates as well as the in vivo efficacy of omadacycline in mice against the multi-drug resistant (MDR) A. baumannii strain 5075 using both a neutropenic thigh infection model and a dorsal wound model of chronic infection relative to the standard of care drugs tigecycline and doxycycline, respectively. In the dorsal wound infection model, the most efficacious dose tested (10 mg/kg twice daily for 6 days) resulted in 100% survival, complete clearance of systemic infection, accelerated wound closure, absence of toxicity, significantly reduced inflammatory cytokine responses, and reduced biofilm formation. These results underscore the potential of omadacycline as a promising therapeutic option for combating MDR A. baumannii infections in chronic wound settings and that additional research is warranted."

Journal • Preclinical • Infectious Disease